SCHEMBL29680263

SCHEMBL29680263

Nc1nc(N)c2nc(-c3cccc(Cl)c3)c(N)nc2n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.68
KDM4E B2RXH2 1/20 0.68
JAK2 O60674 1/20 0.68
GMNN O75496 1/20 0.68
ALDH1A1 P00352 1/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
CYP1A2 P05177 1/20 0.68
GLA P06280 1/20 0.68
CTSG P08311 1/20 0.68
CYP3A4 P08684 1/20 0.68
GAA P10253 1/20 0.68
CYP2D6 P10635 1/20 0.68
CYP2C9 P11712 1/20 0.68
PKM P14618 1/20 0.68
HPGD P15428 1/20 0.68
TSHR P16473 1/20 0.68
ALOX12 P18054 1/20 0.68
NFKB1 P19838 1/20 0.68
SLC6A2 P23975 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triamterene SCHEMBL40707 0.81 ALDH1A1 (1.00) MTORKDM4EJAK2GMNNALDH1A1
Triamterene SCHEMBL29531410 0.81 ALDH1A1 (1.00) MTORKDM4EJAK2GMNNALDH1A1
Triamterene SCHEMBL5421685 0.81 ALDH1A1 (1.00) MTORKDM4EJAK2GMNNALDH1A1
Triamterene SCHEMBL11044581 0.80 ALDH1A1 (0.97) MTORKDM4EJAK2GMNNALDH1A1
SCHEMBL10456550 0.79 PIK3CG (0.87) MTORKDM4EJAK2GMNNALDH1A1
SCHEMBL10843457 0.76 ADORA2A (0.71) CYP2D6MAPK1PMP22CSNK1A1CLK4
Tg100-115 SCHEMBL29411790 0.75 PIK3CG (1.00) MTORKDM4EJAK2GMNNALDH1A1
Tg100-115 SCHEMBL29361550 0.75 PIK3CG (1.00) MTORKDM4EJAK2GMNNALDH1A1
Tg100-115 SCHEMBL360279 0.75 PIK3CG (1.00) MTORKDM4EJAK2GMNNALDH1A1
Tg100-115 SCHEMBL31238338 0.75 PIK3CG (1.00) MTORKDM4EJAK2GMNNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4346928-B1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS US HEALTH (US) 2026-01-14 EP claimed
US-20240271089-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-08-15 US claimed
US-20240261474-A1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-08-08 US claimed
EP-4347795-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2024-04-10 EP claimed
EP-4346928-A1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2024-04-10 EP claimed
WO-2022251477-A1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-12-01 WO claimed
WO-2022251499-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-12-01 WO claimed
EP-4722343-A1 METHOD FOR PRODUCING SUPRACHIASMATIC NUCLEUS ORGANOID Kansai Medical University Educational Corporation (JP) 2026-04-08 EP disclosed
CN-121513013-A Use of Epiblastin A in the manufacture of a medicament for alleviating cisplatin-induced acute kidney injury 南京市儿童医院 2026-02-13 CN disclosed
CN-121513013-A Use of Epiblastin A in the manufacture of a medicament for alleviating cisplatin-induced acute kidney injury 南京市儿童医院 2026-02-13 CN disclosed
EP-4346928-B1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS US HEALTH (US) 2026-01-14 EP disclosed
US-20250027040-A1 METHODS FOR DIFFERENTIATING CELLS BOND UNIVERSITY LTD (AU) 2025-01-23 US disclosed
WO-2024248023-A1 METHOD FOR PRODUCING SUPRACHIASMATIC NUCLEUS ORGANOID 京都府公立大学法人 2024-12-05 WO disclosed
EP-4347795-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2024-04-10 EP disclosed
US-20230416676-A1 Method for Reprogramming Cell MOUCELLION THERAPEUTICS Ltd. (CN) 2023-12-28 US disclosed
EP-4289941-A1 METHOD FOR REPROGRAMMING CELL MOUCELLION THERAPEUTICS Ltd. (CN) 2023-12-13 EP disclosed
WO-2022251477-A1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-12-01 WO disclosed
WO-2022251499-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-12-01 WO disclosed
US-20220177836-A1 METHODS FOR DIFFERENTIATING CELLS BOND UNIVERSITY LTD (AU) 2022-06-09 US disclosed
WO-2022110494-A1 METHOD FOR REPROGRAMMING CELL 北京赛尔湃腾科技咨询合伙企业(有限合伙) 2022-06-02 WO disclosed